The prognostic and predictive value of serum CA19.9 in pancreatic cancer by Humphris, J. L. et al.
Annals of Oncology 23: 1713–1722, 2012
doi:10.1093/annonc/mdr561
Published online 11 January 2012
The prognostic and predictive value of serum CA19.9 in
pancreatic cancer
J. L. Humphris1, D. K. Chang1,2,3, A. L. Johns1, C. J. Scarlett1,4, M. Pajic1, M. D. Jones1,
E. K. Colvin1, A. Nagrial1, V. T. Chin1, L. A. Chantrill1, J. S. Samra5, A. J. Gill6,7, J. G. Kench1,7,8,
N. D. Merrett2,9, A. Das2, E. A. Musgrove1,10, R. L. Sutherland1,10 & A. V. Biankin1,2,3* for the NSW
Pancreatic Cancer Network
1Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst;
2Department of Surgery, Bankstown Hospital, Bankstown;
3South Western Sydney
Clinical School, Faculty of Medicine, University of New South Wales, Liverpool;
4School of Environmental & Life Sciences, University of Newcastle, Ourimbah;
5Departments of Surgery;
6Anatomical Pathology, Royal North Shore Hospital, St Leonards;
7University of Sydney, Camperdown;
8Department of Tissue Pathology and
Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown;
9School of Medicine, University of Western Sydney, Penrith;
10St Vincent’s Clinical School, Faculty of
Medicine, University of New South Wales, Sydney, Australia
Received 28 June 2011; revised 14 October 2011; accepted 18 October 2011
Background: Current staging methods for pancreatic cancer (PC) are inadequate, and biomarkers to aid clinical
decision making are lacking. Despite the availability of the serum marker carbohydrate antigen 19.9 (CA19.9) for over
two decades, its precise role in the management of PC is yet to be deﬁned, and as a consequence, it is not widely
used.
Methods: We assessed the relationship between perioperative serum CA19.9 levels, survival and adjuvant
chemotherapeutic responsiveness in a cohort of 260 patients who underwent operative resection for PC.
Results: By speciﬁcally assessing the subgroup of patients with detectable CA19.9, we identiﬁed potential utility at key
clinical decision points. Low postoperative CA19.9 at 3 months (median survival 25.6 vs 14.8 months, P =0.0052) and
before adjuvant chemotherapy were independent prognostic factors. Patients with postoperative CA 19.9 levels >90 U/
ml did not beneﬁt from adjuvant chemotherapy (P =0.7194) compared with those with a CA19.9 of ≤90 U/ml (median
26.0 vs 16.7 months, P =0.0108). Normalization of CA19.9 within 6 months of resection was also an independent
favorable prognostic factor (median 29.9 vs 14.8 months, P =0.0004) and normal perioperative CA19.9 levels identiﬁed
a good prognostic group, which was associated with a 5-year survival of 42%.
Conclusions: Perioperative serum CA19.9 measurements are informative in patients with detectable CA19.9 (deﬁned
by serum levels of >5 U/ml) and have potential clinical utility in predicting outcome and response to adjuvant
chemotherapy. Future clinical trials should prioritize incorporation of CA19.9 measurement at key decision points to
prospectively validate these ﬁndings and facilitate implementation.
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introduction
Pancreatic cancer (PC) is one of the most lethal solid organ
malignancies. Pancreatectomy offers the only potential for
cure but is only possible in a minority of patients. Even in
those patients who undergo resection, most die because
occult extrapancreatic metastatic disease was likely present
at the time of diagnosis [1]. Systemic therapies are only
modestly effective in advanced disease but have a signiﬁcant
impact in the adjuvant setting, with 5-ﬂuorouracil and
gemcitabine both having efﬁcacy in a subgroup of patients
and increasing 5-year survival from 10%–15% with surgery
alone to 20%–25% [2–5]. As a consequence, there is an
urgent need to develop biomarkers to better stratify patients
for current treatment modalities and for the testing of novel
therapeutic strategies. Carbohydrate antigen 19.9 (CA19.9),
ﬁrst isolated in 1979 [6, 7], is the only available serum
biomarker for PC and has shown some utility as a
diagnostic adjunct and a prognostic marker [8]b u ti sn o t
widely used in routine clinical practice [9]. Serum
biomarkers such as prostate-speciﬁca n t i g e n( P S A )i n
prostate cancer, carcinoembryonic antigen (CEA) in
colorectal cancer and CA 125 in ovarian cancer, which have
similar limitations and although sometimes controversial
are routinely used and are an integral component of clinical
trials in those diseases.
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measurement is robust in predicting prognosis and
chemotherapeutic responsiveness for PC would improve
current management and overall outcomes. Here, we show that
serum CA19.9 has distinct potential clinical utility in PC
patients when assessed at distinct clinical decision points along
the patient journey.
patients and methods
Detailed clinicopathologic and outcome data were collected for 260
consecutive patients who had a histopathologic diagnosis of pancreatic
ductal adenocarcinoma and recorded CA19.9 levels from hospitals
associated with the New South Wales Pancreatic Cancer Network, Australia
(NSWPCN; www.pancreaticcancer.net.au), as previously described [10, 11].
This cohort of patients was retrospectively and then prospectively recruited
when the database was established in 1999. The censor date was 30
September 2010. Ethical approval for the acquisition of data and biological
material was obtained from the Human Research Ethics Committee at each
participating institution. Clinical data were obtained from patients and
family members, hospital notes and physician records. Outcome data
including the date and cause of death were sourced from the NSW Cancer
Registry and treating clinicians.
Survival was measured from the date of histopathologic diagnosis until
date of death or last follow-up. Patients with an R2 resection
(macroscopically positive resection margins) were excluded from the
analysis. All patients were staged based on the American Joint Committee
on Cancer (AJCC) TNM (tumor–node–metastasis) classiﬁcation, 7th
edition [12]. Recurrence was deﬁned by pathological conﬁrmation by
biopsy, cytology or clinical and radiographic ﬁndings consistent with
metastatic disease.
CA19.9 measurement
CA19.9 measurements were carried out at certiﬁed laboratories associated
with the hospital where the patients were treated. The upper limit of
normal used for CA19.9 was 37 U/ml. Red cell phenotyping for Lewis
antigen status was not carried out in the majority of patients; therefore,
patients whose CA19.9 levels were persistently <5 (termed non-expressors)
were deemed likely to be Lewis antigen (Le
a−b−) negative and were
analyzed as a separate group. Paired bilirubin and liver enzymes levels were
also collected. CA19.9 levels may be artiﬁcially elevated in the setting of
cholestasis and correcting it in relation to the bilirubin may improve its
applicability. Signiﬁcant impairment in biliary excretion for which bilirubin
is a surrogate marker occurs when the bilirubin level is >1.5 times the
upper limit of normal (or >2 mg/dl) [13]. Analyses were carried out using
CA19.9 values in patients with normal bilirubin levels and in those with
impaired biliary excretion (bilirubin >2 mg/dl). In patients with bilirubin
>2 mg/dl, the corrected CA19.9 (cCA19.9) was calculated by dividing the
CA19.9 value by the bilirubin (in mg/dl) [13–15].
patient cohort
The cohort consisted of 260 consecutive patients who had a pathological
diagnosis of pancreatic ductal adenocarcinoma who underwent pancreatic
resection with curative intent (macroscopically clear margins). The
clinicopathologic characteristics are summarized in supplementary TableS1
(available at Annals of Oncology online). Clinico-pathologic factors
associated with signiﬁcantly better survival on univariate analysis (Table 1)
included tumors of the pancreatic head (median survival 20.7 versus 11.9
months; P = 0.0053) compared with those of the body/tail, tumor size ≤20
mm (34.4 versus 16.7 months; P = 0.0019), absence of margin involvement
Table 1. Descriptive statistics for patients resected for PC with CA19.9
values (n= 260)
Resected patients with CA19.9 values
Parameter N=260,
No. (%)
Median DSS
(months)
P value
(log-rank)
Sex
Female 123 (47.3) 18.1 0.9721
Male 137 (52.7) 19.4
Age, y
Mean 65.9
Median (range) 67.0 (28–87)
Outcome
Follow-up (mo) 0–115.3
Median follow-up 11.7
30-day mortality 3 (1.2)
Death PC 148 (56.9)
Death other 17 (6.5)
Alive 95 (36.5)
Lost to follow-up 0
Stage
a
IA 7 (2.7) 25.2
IB 10 (3.8) 56.6
IIA 68 (26.2) 22.2
IIB 160 (61.5) 16.9 0.3121
b
III 0 —
IV 15 (5.8) 9.3 0.0002
c
Differentiation
d
Well 23 (8.8) 22.8 0.8527
Moderate 163 (62.7) 18.1
Poor 72 (27.7) 18.6
Missing 2 (0.8)
Tumor location
e
Head 211 (81.2) 20.7 0.0053
Body/tail 49 (18.8) 11.9
Tumor size
f
≤20 mm 44 (16.9) 34.4 0.0019
>20 mm 164 (63.1) 16.7
Missing 52 (20)
Margins
Clear 152 (58.5) 22.8 0.0002
Involved 107 (41.2) 13.2
Missing 1 (0.4)
Lymph nodes
Negative 89 (34.2) 22.2 0.0261
Positive 171 (65.8) 16.8
Perineural invasion
Negative 54 (20.8) 25.6 0.2122
Positive 197 (75.8) 16.8
Missing 9 (3.5)
Vascular invasion
Negative 108 (41.5) 20.7 0.1455
Positive 115 (44.2) 17.8
Missing 37 (14.2)
Adjuvant Chemotherapy
No adjuvant
g 140 (53.8) 16.7
Any adjuvant 120 (46.2) 22.4 0.0029
<3 cycles 35 (13.5) 16.2
≥3 cycles 85 (32.7) 34.3 0.0051
Continued
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(22.2 versus 16.8 months; P = 0.0261), and adjuvant chemotherapy (22.4
versus 16.7 months; P = 0.0029).
Pre-resection CA19.9 values were available in 202 patients and were
taken a median of 0.4 months before surgery. Of these, 10 patients (5%)
had CA19.9 levels <5 pre- and post-resection and in the absence of red cell
phenotyping were deemed non-expressors. Post-resection CA19.9 values
were available in 231 patients but only 131 and 162 patients had levels
carried out within 3 and 6 months of surgery, respectively, and of these, 9
were excluded from the analysis due to being classiﬁed as non-expressors.
Paired pre- and post-resection (within 3 months) CA19.9 values were
available in 88 patients with 3 non-expressors excluded from the analysis.
Paired bilirubin assays at the time of CA19.9 measurement were
available for all patients included in the analysis. Hyperbilirubinemia,
deﬁned as serum level greater than 1.5 times the upper limit of normal (>2
mg/dl or 34.2 μmol/l), was used as a marker of impaired biliary excretion.
In the pre-resection group, the median bilirubin level was 2.0 mg/dL with
hyperbilirubinemia present in 91 (45%). In the post-resection group, the
median bilirubin level was 0.5 mg/dl with hyperbilirubinamia in eight
(6%). In the paired pre- and post-resection group hyperbilirubinamia was
present in 40 (45%) and 2 (2%), respectively.
statistical analysis
Median survival was estimated using the Kaplan–Meier method and the
difference tested using the log-rank test. P values of <0.05 were considered
statistically signiﬁcant. Clinicopathologic variables analyzed with a
signiﬁcant P value and those reported to be signiﬁcant were entered into a
Cox Proportional Hazard multivariate analysis and models resolved using
backward elimination of redundant variables. Statistical analysis was
carried out using Statview 5.0 Software (Abacus Systems, Berkeley, CA).
Disease-speciﬁc survival (DSS) was used as the primary end point.
results
Clinically relevant time points were examined to speciﬁcally
assess a potential role in clinical decision making (ie at 3
months post-resection, within 6 months; before adjuvant
therapy, and after adjuvant therapy). We initially assessed the
value of post-resection CA19.9 in patients who produced
CA19.9 (>5 U/ml) in relation to DSS and subsequently their
response to adjuvant chemotherapy. In addition, we examined
the potential value of preoperative CA19.9 and the change in
level with surgery, with and without adjustment for
hyperbilirubinamia.
prognostic value of CA19.9
post-resection CA19.9 and survival
Of the 122 patients with CA19.9 values at or within 3 months
of surgery, the majority (114; 93%) had bilirubin levels <2 mg/
dl and did not require CA19.9 adjustment. The post-resection
CA19.9 cosegregated with DSS on univariate analysis into three
prognostic groups: (i) those with <37 U/ml had the best
outcome, (ii) 37–120 U/ml, an intermediate outcome, and (iii)
>120 U/ml, the worst outcome (median 25.6 versus 20.7 versus
14.8 months, P= 0.0052; Figure 1A). In the 37–120 U/ml
group, the CA19.9 decreased in ﬁve patients, normalized in
three and increased in ﬁve patients at 6 months, suggesting
that the intermediate group (37–120 U/ml) consisted of those
that had elevated CA19.9 due to other causes as well as
Table 1. Continued
Resected patients with CA19.9 values
Parameter N=260,
No. (%)
Median DSS
(months)
P value
(log-rank)
Median time to adjuvant
chemotherapy (months)
1.8
Chemotherapeutic agent
Gemcitabine monotherapy 89
Gemcitabine+ 5-FU
chemoradiation
13
Gemcitabine+
nab-paclitaxel
1
5-FU monotherapy 6
5-FU chemoradiation 8
Missing 3
Recurrence 166 (63.8)
R0 92 (35.4)
R1 74 (28.5)
Median time to recurrence
(mo)
9.6
R0 12.1
R1 8.0
Palliative chemotherapy 42 (16.2)
Radiotherapy
No radiotherapy 222 (85.4) 18.3
Any radiotherapy 38 (14.6) 19.8 0.6596
h
Adjuvant 29 (11.2) 0.8894
i
Palliative 10 (3.8)
CA19.9
Pre-resection N=202
Median time pre, (mo) 0.4
Post-resection <3/12 N=131
Median time
post <3/12, (mo)
1.2
Post-resection lowest <6/12 N=162
Median time
post <6/12 (mo)
1.9
Pre and post <3/12 N=88
aStaging based on AJCC TNM Staging System, 7th Edition, 2010.
bStage I tumors versus stage II for survival analysis.
cStage I and 2 tumors versus Stage III and IV for survival analysis.
dWell-differentiated and moderately differentiated tumors grouped together
for survival analysis.
ePatients with tumors located in the head of the pancreas underwent
Whipple pancreaticoduodenectomies, and those with tumors of the body/
tail had left-sided pancreatectomies.
fTumor size was also prognostic >30 mm (P=0.0015), and >40 mm (P
<0.0001).
gReasons for not receiving adjuvant chemotherapy: poor performance
status, 18; patient declined, 14; physicians preference, 7; suspected/
conﬁrmed metastatic disease, 4; before 2004 (ESPAC-1 published in 2004
before this adjuvant chemotherapy was not universally accepted as the
standard of care in Australia), 65; not documented post 2004, 32;
hAnalysis compares those patients who received radiotherapy at any time to
all others.
iAnalysis compares those who received adjuvant radiotherapy versus those
who did not.
CA19.9, carbohydrate antigen 19.9; DSS, disease-speciﬁc survival; PC,
pancreatic cancer; 5-FU, 5-ﬂuorouracil.
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within 6 months of resection had a better outcome (median
29.9 versus 14.8 months; P= 0.0004; Figure 1B).
post-resection CA19.9 and recurrence
Of the 122 patients with post-resection CA 19.9 values, 76 had
pathologically clear resection margins (R0), permitting
assessment of disease-free survival (DFS). The median time to
recurrence was 9.0 months (range 0.4–57). DFS paralleled DSS.
Patients with a CA19.9 in the normal range within 3 months
had signiﬁcantly longer DFS than patients with CA19.9 >37 U/
ml (median DFS 22.0 versus 11.5 months, P= 0.0194;
Figure 1C).
pre-resection CA19.9 and survival
The ability to predict prognosis before pancreatectomy would
signiﬁcantly improve outcomes by better selecting patients for
surgery. Preoperative measures of CA19.9 are often
confounded by biliary obstruction, and as a consequence, we
assessed if serum CA19.9 adjusted for hyperbilirubinamia
could be used as a reliable measure of outcome. Of the 202
patients with available pre-resection CA19.9 values, 111 had
paired bilirubin levels <2 mg/dl with a median CA19.9 of 138
Figure 1. Kaplan–Meier survival curves for (A) Post-resection CA19.9 <3 months, (B) Lowest post-resection CA19.9 <6 months, (C) Post-resection CA19.9
<3 months and DFS, (D) Pre-resection CA19.9: normal bilirubin, (E) Pre-resection cCA19.9, (F) Perioperative change cCA19.9. CA19.9, carbohydrate
antigen 19.9; cCA19.9, corrected CA19.9; DFS, disease-free survival.
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<120 U/ml were associated with better DSS (median 35.6 vs
17.4, P= 0.0444; Figure 1D). In the remaining 91 patients with
hyperbilirubinaemia, the median uncorrected and corrected
CA19.9 was 351 and 28, respectively (range 1–101075 and
0.1–16780). Combined uncorrected and corrected pre-
resection cCA19.9 <120 was also associated with a better DSS
(22.2 versus 16.7, P=0.0058; Figure 1E). Table 2 summarizes
the univariate analysis for all categories of CA19.9
measurement. In addition, pre-resection CA19.9 was associated
with pathological stage in patients with normal bilirubin levels
but there was a wide range in CA19.9 values for each stage
with overlap in the values between stages diminishing its
clinical applicability (see Supplementary data, available at
Annals of Oncology online).
perioperative change in CA19.9 and survival
Of the 85 patients with pre- and post-resection cCA19.9 values,
the cCA19.9 level remained <37 U/ml (but >5) in 38 patients,
decreased in 22 patients and increased in 25. These clustered
into three corresponding prognostic groups: (i) <37 U/ml pre-
and post-resection, (ii) a decrease in CA 19.9 and (iii) an
increase in CA 19.9. Patients whose CA 19.9 was always in the
normal range had a better survival compared with the CA 19.9
decrease and increase groups (median survival 26.0 versus 19.6
versus 13.3 months, P=0.0046; Figure 1F; supplementary data,
available at Annals of Oncology online).
multivariate analysis
A multivariate Cox proportional hazards model was developed
using clinicopathologic variables with P <0.05 and those
reported to be prognostic on univariate analysis (Tables 1 and
2). The resolved multivariate model after removal of redundant
variables showed that post-resection CA19.9 >120 U/ml,
positive resection margins, and adjuvant chemotherapy were
independent prognostic factors (Table 3).
Table 2. Univariate analysis of CA19.9 values at signiﬁcant time points
Variable Number Median DSS (months) P value (log-rank)
Prognostic
Post-resection CA19.9 <3/12
<37 U/ml 61 25.6
37–120 U/ml 24 20.7
>120 U/ml 37 14.8 0.0052
Post-resection CA19.9 <6/12
<37 U/ml 77 29.9
>37 U/ml 76 14.8 0.0004
Pre-resection CA19.9 (bilirubin <2 mg/dl)
Non-expressors 10 18.6
<120 U/ml 42 35.6
>120 U/ml 62 17.4 0.0444
Pre-resection cCA19.9
<120 U/ml 107 22.2
>120 U/ml 85 16.7 0.0058
Peri-operative change cCA19.9
<37 pre and post 38 26.0
Any decrease 22 19.6
Any increase 25 13.3 0.0046
Predictive
Pre-adjuvant CA19.9
<90 U/ml 48 26.0
>90 U/ml 19 16.2 0.0190
Pre-adjuvant CA19.9 <90 U/ml
Adjuvant chemotherapy 48 26.0
No adjuvant chemotherapy 23 16.7 0.0108
Pre-adjuvant CA19.9 >90 U/ml
Adjuvant chemotherapy 19 16.2
No adjuvant chemotherapy 16 9.0 0.7194
Post-adjuvant CA19.9
<37 U/ml 11 No patient died from PC
>37 U/ml 8 19.6 Not calculable
Post-resection CA19.9 <3/12—surgery alone
<120 U/ml 40 20.7
>120 U/ml 19 9.0 0.0628
CA19.9, carbohydrate antigen 19.9; PC, pancreatic cancer.
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post-resection CA19.9 and beneﬁt from adjuvant
chemotherapy
Adjuvant chemotherapy was associated with better survival
overall (P=0.0029; Table 1); however, only patients with pre-
adjuvant chemotherapy CA19.9 values <90 U/ml appeared to
beneﬁt. Of 71 patients with a post-resection CA19.9 <90 U/ml
(measured within a month of commencement of adjuvant
therapy or at an equivalent time point for surgery-only
patients), 48 had adjuvant chemotherapy (45 received
gemcitabine-based regimens). In these patients, adjuvant
chemotherapy was associated with a signiﬁcant survival beneﬁt
(median survival 26.0 versus 16.7 months, P= 0.0108;
Figure 2A and 2C). There were 35 patients with post-resection
CA19.9 >90 U/ml. Of these, 19 received adjuvant
chemotherapy, with no statistically signiﬁcant survival beneﬁt
(median survival 16.2 versus 9.0 months, P=0.7194; Table 2
and Figure 2B, D and E). Multivariate analysis of variables
within the CA19.9 <90 U/ml subgroup showed that adjuvant
chemotherapy and size were independent prognostic factors
with involved margins of borderline signiﬁcance (Table 3).
Although numbers were small, early data suggested that
normal CA19.9 levels after completion of adjuvant therapy in
those patients who produce CA19.9 may be associated with an
excellent outcome (Figure 2F). At the censor date, all patients
with post-chemotherapy CA19.9 >37 U/ml had developed
metastatic disease. Two patients were alive with recurrences at
12 and 13 months, respectively, and the remainder had died of
metastatic PC. Of those with post-chemotherapy CA19.9 <37
U/ml, 1 of the 11 patients had developed a recurrence with
peritoneal involvement 48.9 months after the initial resection
(41.6 months after completing chemotherapy).
discussion
Despite its acceptance as a measure of PC tumor burden,
caveats in the interpretation of CA 19.9 values limit application
across the full spectrum of PC. First, CA19.9 is a sialylated
Lewis a (Le
a) antigen. Lewis antigens are normal components
of exocrine epithelial secretions present on erythrocyte
membranes formed from type I oligosaccharide precursors that
undergo sequential addition of monosaccharides by a set of
glycosyltransferases and fucosyltransferases [16]. Two
independent genes determine the Lewis phenotype: the Lewis
gene or α1-4 fucosyltransferase (also known as FUT3) and the
secretor gene or α1-2 fucosyltransferase (FUT2) [17].
Individuals who lack a functional FUT3 allele are termed Lewis
negative (Le
a−b−) and are unable to synthesize CA19.9 [18].
Table 3. Multivariate analysis
Models Variable Hazard ratio (95% CI) P value
Prognostic
A. Resected PC with
CA19.9, initial model (n=260)
Positive lymph nodes 1.69 (0.88–3.25) 0.1124
Size >20 mm 1.45 (0.73–2.86) 0.2862
Poorly differentiated 0.94 (0.47–1.85) 0.8466
Vascular invasion 1.35 (0.71–2.54) 0.3596
Perineural invasion 1.03 (0.54–1.97) 0.9203
Involved margins 2.16 (1.12–4.15) 0.0207
Adjuvant chemotherapy 0.65 (0.37–1.15) 0.1346
Pre-resection cCA19.9 >120 U/ml 1.27 (0.70–2.32) 0.4296
Post-resection CA19.9 >120 U/ml (≤3 months) 2.47 (1.37–4.44) 0.0026
B. Resected PC with
CA19.9, resolved model (n=260)
Positive lymph nodes 1.53 (0.99–2.35) 0.0553
Size >20 mm 1.61 (0.99–2.62) 0.0555
Involved margins 1.79 (1.15–2.77) 0.0090
Adjuvant chemotherapy 0.60 (0.39–0.92) 0.0198
Post-resection CA19.9 >120 U/ml (≤3 months) 1.87 (1.20–2.92) 0.0056
C. Resected PC with
CA19.9, ﬁnal model (n= 260)
Involved margins 2.19 (1.47–3.27) 0.0001
Adjuvant chemotherapy 0.61 (0.40–0.91) 0.0172
Post-resection CA19.9 >120 U/ml (≤3 months) 1.90 (1.25–2.91) 0.0029
Predictive
D. Pre-adjuvant CA19.9
<90, initial model (n=78)
Positive lymph nodes 1.09 (0.51–2.30) 0.8315
Size >20 mm 2.52 (1.15–5.52) 0.0209
Poorly differentiated 1.11 (0.53–2.31) 0.7793
Vascular invasion 1.09 (0.53–2.22) 0.8125
Perineural invasion 2.20 (0.94–5.12) 0.0693
Involved margins 1.69 (0.85–3.36) 0.1334
Adjuvant chemotherapy 0.27 (0.13–0.55) 0.0004
E. Pre-adjuvant CA19.9
<90, resolved model (n=78)
Size >20 mm 2.56 (1.20–5.46) 0.0146
Involved margins 1.94 (1.00–3.79) 0.0509
Adjuvant chemotherapy 0.28 (0.14–0.57) 0.0004
CA19.9, carbohydrate antigen 19.9; cCA19.9, corrected CA19.9; CI, conﬁdence interval; PC, pancreatic cancer.
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higher in other populations such as Africans (22%) [17, 18].
Individuals with at least one functional FUT3 allele are
characterized by the red cell phenotype Le
a+b− or Le
a−b+
(rarely Le
a+b+). Lack of a functional FUT2 allele leads to the
non-secretor phenotype (se/se), which is characterized by the
absence of ABH determinants in saliva and on some epithelial
cell types [16]. Non-secretors in general have higher serum and
urine CA19.9 levels than secretors [19]. Second, CA 19.9 can
also be elevated in benign pancreatic diseases such as
pancreatitis [20], which often coexist with PC. Third, CA19.9
undergoes some degree of biliary excretion and is produced by
biliary epithelial cells. Therefore, in the setting of cholestasis,
CA19.9 levels are frequently elevated even in benign conditions
[21].
Serum CA19.9 possesses many features of a robust or
clinically useful biomarker and has been well studied to deﬁne
its limitations outlined above. Despite this, there are no clear
Figure 2. Kaplan–Meier survival curves for (A) Pre-adjuvant CA19.9 <90, (B) Pre-adjuvant CA19.9 >90, (C) Adjuvant chemotherapy CA19.9, (D) No
adjuvant chemotherapy CA19.9, (E) Pre-adjuvant CA19.9—stratiﬁed by chemotherapy, (F) Post-adjuvant chemotherapy CA19.9. CA19.9, carbohydrate
antigen 19.9.
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for other similar serum biomarkers such as PSA for prostate
cancer, CEA for colorectal cancer and CA 125 in ovarian
cancer, which are although sometimes controversial, used in
routine practice and form integral components of clinical trials
to further advance clinical management. We focused on
deﬁning potential roles for serum CA19.9 at key clinical
decision-making time points in patients who have
demonstrable CA19.9 production. If an individual is identiﬁed
to have the capacity to produce CA19.9, either through Lewis
antigen testing or through a level over 5 U/ml at diagnosis as a
surrogate, postoperative CA19.9 measurements have potential
prognostic and predictive value. First, normalization of CA19.9
postoperatively is associated with a good prognosis. Second,
postoperative CA19.9 levels >90 U/ml may be associated with a
lack of response to adjuvant gemcitabine-based chemotherapy,
and third, although numbers are small, a normal CA19.9 after
completion of adjuvant therapy is potentially associated with
an excellent prognosis. These potential applications are
summarized in Figure 3, which also proposes how CA19.9
levels could be incorporated in to trials to inform clinical
decision making.
prognostic value of CA19.9
Postoperative CA19.9 measurements at 3 months (when
hyperbilirubinamia is uncommon) co-segregate into three
prognostic groups. The intermediate prognostic group of 37–
120 U/ml at that time likely includes a mix of those with
progressive disease and other causes of increased CA19.9 levels
(biliary dysfunction and pancreatitis). This group declares itself
by the 6-month stage to segregate into two prognostic groups
dichotomized by the normal reference value (37 U/ml). In
addition, a normal level both pre- and postoperatively
identiﬁes a group with the best prognosis, which has a 5-year
survival of 42%.
The key element of the present study is that potential clinical
utility was directly examined by assessing CA19.9 at speciﬁc
decision-making time points. Overall, although not directly
comparable, our ﬁndings with regard to the prognostic value of
CA19.9 are supported by evidence from retrospective cohorts
and in clinical trials. In patients undergoing pancreatic
resection for PC, the preoperative CA19.9 value is associated
with tumor stage, resectability, risk of recurrence and survival
[13, 22–26]. Even with intercurrent biliary obstruction, which
is present in ∼50% of patients, adjustment of CA19.9 levels
relative to the degree of hyperbilirubinamia may still have
potential prognostic value and further evaluation is
encouraged. The postoperative level and the change in CA19.9
have also been correlated with survival and risk of recurrence
[27–31]. Evidence is emerging that post-resection CA19.9
velocity, akin to PSA doubling time in prostate cancer, may be
a better predictor of recurrence and survival [32]. In addition,
for nonresectable patients, the CA19.9 at the time of diagnosis
is also a prognostic factor [33].
predictive value of CA19.9
In patients undergoing systemic chemotherapy for advanced
PC, the change in CA19.9 correlates with objective
(radiographic) response and survival [34–37]. The poor
survival of the majority of patients even with clinically
localized PC who undergo resection is likely due to occult
metastatic disease at the time of diagnosis. Based on the
rationale of adjuvant therapy targeting low-volume disease and
that serum CA19.9 is a measure of disease burden, CA19.9
may have predictive value in the adjuvant setting. A key
ﬁnding in our study is that patients with a post-resection
CA19.9 >90 U/ml did not achieve long-term beneﬁtf r o m
adjuvant chemotherapy, whereas those with CA 19.9 <90 U/ml
did. Previous studies have generally not addressed the
relationship between CA19.9 and response to adjuvant therapy;
however, assumptions were made and selection criteria altered
based on CA 19.9 levels. In CONKO-001, which compared
adjuvant gemcitabine to observation, patients with
postoperative CA19.9 values >2.5 times the upper limit of
normal (≈90 U/ml) were excluded.[4] In contrast, no CA19.9
exclusion criteria were used in ESPAC-1 and ESPACas-3 or
RTOG-9704 [2, 3, 5]. In the analysis of CA19.9 data from the
RTOG-9704 study of gemcitabine versus 5-FU before and after
chemoradiation, Berger et al. [29] identiﬁed that patients with
a CA19.9 >90 U/ml had a poor survival (23.0 versus 10.4
months). Our results suggest that patients with a post-resection
CA19.9 >90 U/ml do not obtain long-term beneﬁtf r o m
current systemic chemotherapy regimens and support
integration of CA19.9 testing pre- and post-adjuvant therapy to
deﬁne its role as a predictive marker and a surrogate end point.
In conclusion, assessing serum CA19.9 at speciﬁc clinically
relevant time points while cognizant of its limitations has
signiﬁcant potential utility. These strategies should be
incorporated into future clinical trials as a priority, which will
deﬁne its precise role in the routine management of pancreatic
cancer, and like PSA for prostate cancer, potentially become
part of routine clinical practice.
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